Caligan Partners LP
Q3 2025 13F-HR Holdings
Net value change ($000)
+243,341
(46.8%)
New positions
5
Sold out positions
5
Turnover %
33.7%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q2 2025
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| ABVX | 110,459 | 862.4% |
| LQDA | 83,463 | 82.5% |
| MLYS | 77,844 | 285.2% |
| ADMA | 38,653 | NEW |
| RVMD | 26,271 | 112.1% |
| XENE | 17,849 | NEW |
| AVTX | 10,592 | NEW |
| AGIO | 9,777 | 27.4% |
| INBX | 7,961 | NEW |
| TYRA | 7,931 | 436.2% |
Top Reduces (Value $000, Stocks/ETFs)
| VRNA | -135,900 | -100.0% |
| Merus N.V. | -14,132 | -40.9% |
| Y-mAbs Therapeutics, Inc. | -10,565 | -100.0% |
| RZLT | -6,882 | -100.0% |
| BCRX | -5,725 | -100.0% |
| EOLS | -5,367 | -17.4% |
| VRCA | -4,898 | -100.0% |
| EXEL | -4,234 | -6.3% |
| ANIK | -1,694 | -11.2% |
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000):
42,840
(5.6% of total reported value)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|